JPMorgan Resumes Nektar Therapeutics (NKTR) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $37.76 --0%
Rating Summary:
21 Buy, 9 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 12
Rating Summary:
21 Buy, 9 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 12
Join SI Premium – FREE
JPMorgan analyst Jessica Fye resumes coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Neutral rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.
Shares of Nektar Therapeutics closed at $18.82 yesterday.
You May Also Be Interested In
- Jefferies Starts Core & Main Inc. (CNM) at Buy
- Goldman Sachs Assumes Skyworks Solutions (SWKS) at Sell
- Jefferies Starts Aura Consolidated Group (AXQ:AU) at Hold
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
